Digital Tech as a CDMO Differentiator genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Thermo Fisher (TMO) Expands in Viral Vector With Henogen Buyout Zacks.com 1/18/2021
In an effort to expand its cell and gene vaccines and therapies footprint internationally,
Thermo Fisher Scientific Inc. TMO recently acquired Belgium-based Henogen S.A. Henogen is the viral vector manufacturing business of life sciences service and technology supplier, Groupe Novasep SAS.
Popular Searches
Per the financial terms of the deal, Thermo Fisher completed this acquisition for a deal value of approximately €725 million (roughly $880 million) in cash. This business will get integrated within Thermo Fisher’s Pharma Services business within the broader Laboratory Products and Services Segment.
A Glimpse of Henogen’s Business
Thermo Fisher Acquires Novasep s Viral Vector Manufacturing Business For 725 Mln Euros
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Thermo Fisher Scientific Inc. (TMO) has completed the acquisition of Henogen S.A., Groupe Novasep SAS s viral vector manufacturing business in Belgium for about 725 million euros in cash, the two companies said Friday.
Novasep s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies as well as large biopharma customers. The business will be part of Thermo Fisher s Pharma Services business within the Laboratory Products and Services Segment.
Novasep s viral vector business has two locations in Seneffe and Gosselies, Belgium. It offers more than 7,000 square meters of clinical and commercial manufacturing capacity.